Mr. Qiang Jing is currently the president of SinoMab BioScience Limited (3681. HK).

From 2010 to 2017, Mr. Qiang served as a Managing Director and the Head of research in medicine and healthcare of the Research Department of China International Capital Corporation Limited (“CICC”). During his tenure at CICC, Mr. Qiang won the first place in Asiamoney for healthcare of Asia region in 2017, and the first place for healthcare of Mainland China and Hong Kong for four consecutive years from 2014 to 2017. From 2015 to 2016, he was ranked the top three in the Greater China by Institutional Investor.

Mr. Qiang is a Chartered Financial Analyst (CFA) and a Certified Financial Risk Manager (FRM). Mr. Qiang had a further research of tumor biology at Harvard Medical School and majored in finance at Tsinghua University for his PhD; In 2010, he graduated from Fudan University with a Master's degree in finance and graduated from Shanghai Jiao Tong University in 2005 with a Bachelor's degree in pharmacy.